Immunome, Inc. Stock Split Ratio
Immunome, Inc. (IMNM) reported Stock Split Ratio of 16.67% for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2021-11-15
- Immunome, Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2021-03-31 was 16.67%.
- Immunome, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2020 was 16.67%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|
| 2021-09-30 | 16.67% 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 16.67% 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | 16.67% 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | 16.67% 10-K · filed 2021-03-25 | |||
| 2020-09-30 | 600.00% 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |